AlphaRET 2RT – Oftalmedica

RETINA REJUVENATION – NATURALLY

2RT™ (Retinal Rejuvenation Therapy) is a proprietary, patented laser therapy that stimulates the eye's natural healing response to treat degenerative retinal diseases, including early stages of AMD. 2RT™ features proprietary Nanopix™ technology, which pairs a nanosecond laser pulse with a unique pixelated beam profile to exclusively target select single cells within the retinal pigment epithelium.

Clinically proven to delay AMD

The Laser Intervention in Early AMD (LEAD) clinical trial, a large randomized, controlled clinical trial, demonstrated the potential of 2RT™ to significantly reduce the rate of disease progression in a specific group of patients with intermediate AMD. 1 Specifically, post hoc analyzes demonstrated that in patients who did not have coexisting reticular pseudodrusen (RPD), a fatty deposit associated with later stages of AMD (76% of enrolled patients), treatment with 2RT™ produced a clinically significant result 77 Percentage reduction in the rate of disease progression.

AMD - previous surgery

2RT™ offers the possibility of intervening early in the pathological process to improve retinal function and therefore slow down the degenerative processes associated with AMD in its early stages. Clinical and scientific studies demonstrate that 2RT™ can induce a mononuclear cell response in the early intervention of AMD, including stimulation of microglia. 1,2

CSME – thermal damage avoided

Unlike conventional retinal photocoagulation, which can cause permanent damage to sensitive structures in the eye, 2RT™ uses 500 times less energy than retinal photocoagulation and eliminates the incidence of thermal damage to the retina and surrounding cells in the effective treatment of clinically significant macular edema (CSME). 3

References:

1. Jobling et al., “Nanosecond Laser Therapy Reverses Pathological and Molecular Changes in Age-Related Macular Degeneration Without Retinal Damage,” The FASEB Journal 29, no. 2 (1 February 2015): 696–710, doi:10.1096/fj.14-262444.

2. Guymer, R.H., et al., Application of nanosecond laser in intermediate AMD: 12-month outcomes of fundus appearance and macular function. Clin Experiment Ophthalmol. 3 October 2013 doi: 10.1111/ceo.12247.

3. Casson RJ. et al., “Randomized Pilot Trial of a Nanopulsed Retinal Laser Compared to Conventional Photocoagulation for the Treatment of Diabetic Macular Edema,” Clin Experiment Ophthalmol. 2012 August;40(6):604-10

VISIT THE SITE